- Home
- TKNO vs GOSS Comparison
TKNO vs GOSS Comparison
Compare TKNO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- GOSS
- Stock Information
- Founded
- TKNO 1996
- GOSS 2015
- Country
- TKNO United States
- GOSS United States
- Employees
- TKNO N/A
- GOSS N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- GOSS Health Care
- Exchange
- TKNO Nasdaq
- GOSS Nasdaq
- Market Cap
- TKNO 256.9M
- GOSS 347.8M
- IPO Year
- TKNO 2021
- GOSS 2019
- Fundamental
- Price
- TKNO $4.35
- GOSS $2.47
- Analyst Decision
- TKNO
- GOSS Strong Buy
- Analyst Count
- TKNO 0
- GOSS 4
- Target Price
- TKNO N/A
- GOSS $8.50
- AVG Volume (30 Days)
- TKNO 224.0K
- GOSS 3.1M
- Earning Date
- TKNO 08-07-2025
- GOSS 08-05-2025
- Dividend Yield
- TKNO N/A
- GOSS N/A
- EPS Growth
- TKNO N/A
- GOSS N/A
- EPS
- TKNO N/A
- GOSS N/A
- Revenue
- TKNO $38,923,000.00
- GOSS $40,237,000.00
- Revenue This Year
- TKNO $9.52
- GOSS N/A
- Revenue Next Year
- TKNO $15.20
- GOSS $30.65
- P/E Ratio
- TKNO N/A
- GOSS N/A
- Revenue Growth
- TKNO 11.40
- GOSS N/A
- 52 Week Low
- TKNO $4.00
- GOSS $0.66
- 52 Week High
- TKNO $10.37
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- GOSS 68.08
- Support Level
- TKNO $4.22
- GOSS $2.38
- Resistance Level
- TKNO $4.94
- GOSS $2.65
- Average True Range (ATR)
- TKNO 0.29
- GOSS 0.15
- MACD
- TKNO -0.00
- GOSS 0.03
- Stochastic Oscillator
- TKNO 16.75
- GOSS 76.67
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.